cbdMD profit margin YCBD
Gross, operating and net profit as a share of revenue over the last twelve months, from 2017.
- Net margin, 12 months
- −13.8%
- Operating margin, 12 months
- −13.9%
- Net margin on a year earlier
- −5.8 pts
- Peer median
- 8.9%
Over the twelve months to Jun 30, 2026, cbdMD kept −13.8% of its revenue as net profit, with an operating margin of −13.9% and a gross margin of 57.7%.
Five years earlier its net margin was −57.4%.
The median for 4 consumer staples stocks of a similar size is 8.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −10.6% | −11.3% | 62.4% |
| FY2024 | −19.0% | −17.0% | 61.6% |
| FY2023 | −95.0% | −93.1% | 62.0% |
| FY2022 | n/a | n/a | 63.1% |
| FY2021 | −52.6% | −44.1% | 67.4% |
| FY2020 | 30.1% | −42.0% | 63.0% |
| FY2019 | n/a | −62.6% | 61.4% |
| FY2018 | 0.7% | −21.3% | 68.3% |
| FY2017 | −31.0% | n/a | 69.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q3 FY26 | −13.8% | −5.8 pts | −13.9% | |
| Q2 FY26 | −13.3% | −12.5 pts | −13.4% | |
| Q1 FY26 | −12.3% | +1.7 pts | −12.4% | |
| Q4 FY25 | −10.6% | +8.4 pts | −11.3% | |
| Q3 FY25 | −8.0% | +86.2 pts | −9.4% | |
| Q2 FY25 | −0.8% | n/a | −6.5% | |
| Q1 FY25 | −14.0% | +71.2 pts | −12.2% | |
| Q4 FY24 | −19.0% | +76.0 pts | −17.0% | |
| Q3 FY24 | −94.1% | −11.6 pts | −88.3% | |
| Q2 FY24 | n/a | n/a | −91.1% | |
| Q1 FY24 | −85.2% | n/a | −83.2% | |
| Q4 FY23 | −95.0% | n/a | −93.1% |
Against its peers
Companies in Consumer Defensive nearest cbdMD's size, closest first, today.
| Company | Profit margin |
|---|---|
| YCBDcbdMD | −13.8% |
| EDUCEducational Development | 8.6% |
| JVACoffee | 4.9% |
| RAVERave Restaurant | 22.3% |
| AXILAxil Brands | 9.3% |
| Peer median | 8.9% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on cbdMD
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.